Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with ...

Excessive use of digital devices and mental health issues can both contribute to the development of dry eye syndrome.

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, shares how health care leaders are advancing value-based care through improved data strategies, ...

Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to ...

US migrant populations experience various dermatologic conditions linked to exposures before, during, and after migration, ...

Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in ...

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy, highlights key policy updates that are impacting managed care pharmacy.